EPIVIR-HBV
LOE ApproachingNDAORALSOLUTIONPriority Review
Approved
Dec 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPIVIR-HBV is an oral nucleoside reverse transcriptase inhibitor (NRTI) approved for chronic hepatitis B infection. The active ingredient is lamivudine, which inhibits HBV reverse transcriptase to reduce viral replication. It is formulated as an oral solution for patient convenience.
LOE Approaching
LOE-approaching product with moderate competitive pressure (30%) suggests consolidating market position and managing transition planning for brand teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate this product is in steady-state or wind-down mode, offering limited growth opportunities. Professionals on EPIVIR-HBV should anticipate eventual transition to portfolio products or transition roles as LOE approaches.
Brand ManagerField Sales
Worked on EPIVIR-HBV at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.